ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has successfully concluded its series C financing round, bringing the total amount raised since its start close to 20 million euros. The proceeds from the series C financing will be used to generate solid clinical data with a second vaccine in swine as well as with its BVD antiviral drug in cattle.
ViroVet pioneers in developing novel and innovative vaccines based on a unique proprietary technology platform originating from the Rega Institute for Medical Research of KU Leuven. With this technology platform, vaccines can be designed and produced faster and more cost-effectively. The vaccines are tailor-made and are thermostable thereby removing any cold-chain requirement. ViroVet has already obtained proof-of-concept in a challenge study with JEV and is now preparing scale-up of vaccine production.
The company also continues the development of its extended release BVD antiviral drug. A transmission study is scheduled for later this year in the United States.
Erwin Blomsma, PhD, co-founder and CEO of ViroVet states that “We are gratified with the support of our current investors. As additional clinical data will be generated in our priority programs, exciting times are ahead”
George Gunn, Chairman of the Board: “The series C will allow the team to generate data around the key products building value to a point where strategic options become attractive”